ST-001 nanoFenretinide
Cancer (hematologic malignancies & solid tumors)
Phase 1Active
Key Facts
Indication
Cancer (hematologic malignancies & solid tumors)
Phase
Phase 1
Status
Active
Company
About SciTech Development
SciTech Development has developed a proprietary nanoparticle Drug Delivery Platform (SDP) designed to enhance the bioavailability of water-insoluble therapeutics, particularly in oncology. Its lead program, ST-001 nanoFenretinide, reformulates the investigational drug fenretinide for intravenous delivery, aiming to unlock its full clinical potential in cancers where low bioavailability has historically been a barrier. The company is clinical-stage, supported by NCI funding, and is seeking partnerships and funding to advance trials, with an estimated 2-3 year path to market for its lead asset. The SDP platform also holds potential for delivering other insoluble drugs beyond oncology.
View full company profile